{"id":"bisdequalinium-chloride","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T16:38:05.650502","allNames":"bisdiqualinium chloride","offLabel":[],"synonyms":["bisdequalinium chloride","bisdiqualinium chloride"],"timeline":[],"brandName":"Bisdiqualinium Chloride","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine bisdequalinium chloride as a key that fits into a specific lock on a cell. When it binds to this lock, it can either turn off or turn on certain cellular processes, depending on the specific target it interacts with. This can help to either reduce or increase the activity of certain cellular pathways, leading to therapeutic effects.","oneSentence":"Bisdequalinium chloride is thought to work by interacting with specific cellular targets to produce its therapeutic effects.","technicalDetail":"Bisdequalinium chloride is a small molecule that likely interacts with specific cellular targets, such as ion channels or receptors, to produce its therapeutic effects. The exact mechanism of action is unknown, but it is thought to involve the modulation of cellular signaling pathways."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3030","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bisdequalinium chloride","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:00:22.380061","biosimilars":[],"competitors":[],"genericName":"bisdequalinium chloride","indications":{"approved":[],"offLabel":[],"pipeline":[]},"_fixedFields":["pubmed(1)"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"INQ1WJ5T1A","CHEBI":"CHEBI:135886","UMLSCUI":"C0106539","PUBCHEM_CID":"19598959"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2023","pmid":"37556478","title":"Polypharmacology guided drug repositioning approach for SARS-CoV2.","journal":"PloS one"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Bisdequalinium chloride is a small molecule modality developed by a pharmaceutical company. However, due to the lack of available information, its target, drug class, and approved indications are unknown. Its commercial status, including whether it is patented or generic, and whether it is off-patent, is also unclear. Further research is needed to determine its key safety considerations and pharmacokinetic properties. As a result, bisdequalinium chloride remains a relatively unknown compound in the pharmaceutical industry.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}